It is worth noting that NSC59984, a small molecule that induces degradation of mutated p53 protein through the MDM2 and ubiquitin–proteasome pathways, has been used in combination with CPT-11 to synergistically induce cell death in CRC cells expressing p53 mutant, indicating a promising therapeutic strategy (Zhang et al. 2015). This evidence concerns the gene TP53 and colorectal carcinoma.